Foundations Investment Advisors LLC Lowers Holdings in Medtronic PLC $MDT

Posted by Brenda Bartman on May 30th, 2026

Foundations Investment Advisors LLC decreased its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 18.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 41,872 shares of the medical technology company’s stock after selling 9,198 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Medtronic were worth $4,022,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Lodestone Wealth Management LLC purchased a new stake in Medtronic in the fourth quarter worth about $27,000. Anfield Capital Management LLC raised its holdings in shares of Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Medtronic in the 4th quarter worth approximately $29,000. GoalVest Advisory LLC purchased a new stake in shares of Medtronic in the 4th quarter worth approximately $29,000. Finally, Valley Wealth Managers Inc. bought a new position in shares of Medtronic during the third quarter valued at approximately $29,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

Shares of NYSE MDT opened at $73.73 on Friday. Medtronic PLC has a fifty-two week low of $73.67 and a fifty-two week high of $106.33. The company has a market cap of $94.66 billion, a PE ratio of 20.54, a P/E/G ratio of 1.80 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The business has a 50-day simple moving average of $82.36 and a two-hundred day simple moving average of $92.65.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.9%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s payout ratio is currently 79.11%.

Analysts Set New Price Targets

A number of equities analysts recently commented on MDT shares. UBS Group reduced their price objective on shares of Medtronic from $104.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, April 22nd. Weiss Ratings cut Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. The Goldman Sachs Group set a $84.00 price target on Medtronic and gave the stock a “neutral” rating in a research report on Thursday, May 21st. Jefferies Financial Group restated a “hold” rating and set a $95.00 price objective on shares of Medtronic in a research note on Thursday, April 23rd. Finally, Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $106.45.

View Our Latest Stock Report on Medtronic

Medtronic Company Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).